H.C. Wainwright analyst Robert Burns upgraded Karyopharm (KPTI) to Buy from Neutral with a $15 price target The company’s al strategic financing and capital structure transactions last week remove an overhang on the shares, the analyst tells investors in a research note. The firm says Karyopharm has extended its operational runway beyond the top-line readout from the Phase 3 SENTRY trial.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KPTI:
- Karyopharm price target lowered to $21 from $25 at Baird
- Karyopharm Therapeutics: Strategic Financing Extends Cash Runway Amid Cautious Hold Rating
- Karyopharm price target lowered to $6 from $8 at Leerink
- Morning Movers: AST SpaceMobile jumps after direct-to-cellular pact with Verizon
- Karyopharm Secures $100M Financing for Clinical Trials